Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Aged
Aged, 80 and over
Antineoplastic Agents
/ adverse effects
Carcinoma, Hepatocellular
/ complications
Female
Humans
Liver Neoplasms
/ complications
Male
Phenylurea Compounds
/ adverse effects
Prognosis
Psoas Muscles
/ diagnostic imaging
Quinolines
/ adverse effects
Retrospective Studies
Sarcopenia
/ complications
Survival Analysis
Tomography, X-Ray Computed
Hepatocellular carcinoma
Lenvatinib
Pre-sarcopenia
Prognosis
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
19
09
2020
received:
17
07
2020
accepted:
04
11
2020
pubmed:
11
11
2020
medline:
15
12
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
This study aimed to elucidate the clinical importance of muscle volume loss (pre-sarcopenia) in patients receiving lenvatinib as treatment for unresectable hepatocellular carcinoma (u-HCC). Of 437 u-HCC patients treated with lenvatinib at specific institutions in Japan between March 2018 and May 2020, 151 with available computed tomography imaging data from the time of lenvatinib introduction were enrolled. Pre-sarcopenia was diagnosed based on a previously reported cut-off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm Cox hazard multivariate analysis showed alpha-fetoprotein (≥400 ng/mL) (hazard ratio [HR] 2.271, P < 0.001), Barcelona Clinic Liver Cancer stage (C and D) (HR 1.625, P = 0.018), and positive for pre-sarcopenia (HR 1.652, P = 0.042) to be significant prognostic factors. OS rates for the pre-sarcopenia group (n = 41) were worse than those for the non-pre-sarcopenia group (n = 110) (0.5-, 1-, and 1.5-year OS: 72.5%, 27.9%, and 7.0% vs 80.7%, 56.7%, and 46.1%, respectively; P < 0.001), as was progression-free survival (P = 0.025). Time to stopping lenvatinib or disease progression was better in the non-pre-sarcopenia group (0.5-, 1-, and 1.5-year OS: 48.0%, 24.5%, and 8.4% vs 20.0%, 10.3%, and 4.2%, respectively; P < 0.001). Also, the frequency of the adverse event appetite loss (any grade) was greater in the pre-sarcopenia group (43.9% vs 18.2%, P = 0.003). Pre-sarcopenia was shown to be a significant prognostic factor in patients treated with lenvatinib for u-HCC.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
This study aimed to elucidate the clinical importance of muscle volume loss (pre-sarcopenia) in patients receiving lenvatinib as treatment for unresectable hepatocellular carcinoma (u-HCC).
METHODS
METHODS
Of 437 u-HCC patients treated with lenvatinib at specific institutions in Japan between March 2018 and May 2020, 151 with available computed tomography imaging data from the time of lenvatinib introduction were enrolled. Pre-sarcopenia was diagnosed based on a previously reported cut-off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm
RESULTS
RESULTS
Cox hazard multivariate analysis showed alpha-fetoprotein (≥400 ng/mL) (hazard ratio [HR] 2.271, P < 0.001), Barcelona Clinic Liver Cancer stage (C and D) (HR 1.625, P = 0.018), and positive for pre-sarcopenia (HR 1.652, P = 0.042) to be significant prognostic factors. OS rates for the pre-sarcopenia group (n = 41) were worse than those for the non-pre-sarcopenia group (n = 110) (0.5-, 1-, and 1.5-year OS: 72.5%, 27.9%, and 7.0% vs 80.7%, 56.7%, and 46.1%, respectively; P < 0.001), as was progression-free survival (P = 0.025). Time to stopping lenvatinib or disease progression was better in the non-pre-sarcopenia group (0.5-, 1-, and 1.5-year OS: 48.0%, 24.5%, and 8.4% vs 20.0%, 10.3%, and 4.2%, respectively; P < 0.001). Also, the frequency of the adverse event appetite loss (any grade) was greater in the pre-sarcopenia group (43.9% vs 18.2%, P = 0.003).
CONCLUSION
CONCLUSIONS
Pre-sarcopenia was shown to be a significant prognostic factor in patients treated with lenvatinib for u-HCC.
Identifiants
pubmed: 33171524
doi: 10.1111/jgh.15336
pmc: PMC8359359
doi:
Substances chimiques
Antineoplastic Agents
0
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1812-1819Informations de copyright
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Liver Cancer. 2017 Jun;6(3):204-215
pubmed: 28626732
Dig Dis. 2015 Oct;33(6):765-70
pubmed: 26488173
Radiology. 2010 Sep;256(3):806-16
pubmed: 20720069
Hepatol Res. 2017 Mar;47(3):E22-E34
pubmed: 27062043
J Gastroenterol Hepatol. 2021 Jul;36(7):1812-1819
pubmed: 33171524
Hepatol Res. 2017 May;47(6):558-565
pubmed: 27480045
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Gastroenterol Hepatol. 2016 May;31(5):1031-6
pubmed: 26647219
Stat Med. 2005 Oct 30;24(20):3089-110
pubmed: 16189810
J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):347-354
pubmed: 30793533
J Gastroenterol. 2003;38(3):207-15
pubmed: 12673442
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Liver Cancer. 2020 Jan;9(1):73-83
pubmed: 32071911
J Clin Oncol. 2010 Feb 20;28(6):1054-60
pubmed: 20085939
J Gastroenterol Hepatol. 2018 Jun;33(6):1271-1276
pubmed: 29193248
Cancers (Basel). 2019 Aug 19;11(8):
pubmed: 31430945
Oncology. 2019;97(5):277-285
pubmed: 31307035
J Gastroenterol Hepatol. 2011 Apr;26(4):616-8
pubmed: 21418298
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Liver Cancer. 2019 Mar;8(2):121-129
pubmed: 31019902
Oncol Lett. 2010 Jan;1(1):57-61
pubmed: 22966256
Liver Cancer. 2020 Apr;9(2):193-206
pubmed: 32399433
J Gastroenterol. 2015 Dec;50(12):1206-13
pubmed: 25820219
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Liver Cancer. 2019 Jul;8(4):255-270
pubmed: 31602369
Liver Cancer. 2017 Nov;6(4):325-336
pubmed: 29234636
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Liver Cancer. 2020 Jan;9(1):1-5
pubmed: 32071904
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancer Med. 2019 Jul;8(8):3719-3728
pubmed: 31127698
Liver Cancer. 2015 Mar;4(1):39-50
pubmed: 26020028
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Lancet Oncol. 2019 Apr;20(4):e191
pubmed: 30942178
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
PLoS One. 2018 Jun 18;13(6):e0198812
pubmed: 29912922
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Liver Cancer. 2020 Apr;9(2):148-155
pubmed: 32399429
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1416-1423
pubmed: 29016470
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):559-65
pubmed: 17255278
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Liver Cancer. 2018 Mar;7(1):90-103
pubmed: 29662836
Int J Cancer. 2001 Oct 15;94(2):153-6
pubmed: 11668491
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Radiology. 2011 Dec;261(3):834-44
pubmed: 21998047
Oncology. 2019;97(6):334-340
pubmed: 31466068